Royalty Pharma plc (RPRX) FY2025 Q1 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2025-03-31

Swipe to see the full flow
Royalty Pharma plc (RPRX) FY2025 Q1 Balance SheetBalance sheet as of 2025-03-31. The chart shows assets, liabilities and equity at that date.Current assets$1.84 BCurrent liabilities$1.18 BLiabilities$7.82 BAssets$17.61 BNon-current liabilities$6.64 BNon-current assets$15.77 BEquity$9.79 BGross equity(calculated)$9.79 BHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSCash and cash equivalentsFinancial royalty assetsOther royalty income receivableAvailable for sale debt securitiesOther current assetsFinancial royalty assets, netEquity method investmentsAvailable for sale debt securitiesEquity securitiesOther assetsCurrent portion of long-term debtDistributions payable to non-controlling interestsAccounts payable and accrued expensesInterest payableOther current liabilitiesLong-term debtOther liabilitiesAdditional paid-in capitalRetained earningsCommon stock - Class R Redeemable SharesCommon stock - Class A Ordinary SharesNon-controlling interestsCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Treasury interestsCurrent portion of long-term debtCurrent portion of long-term debt$998.61 MCash and cash equivalentsCash and cash equivalents$1.09 BDistributions payable to non-controlling interestsDistributions payable to non-controlling interests$108.80 MCurrent assetsCurrent assets$1.84 BFinancial royalty assetsFinancial royalty assets$716.56 MCurrent liabilitiesCurrent liabilities$1.18 BAccounts payable and accrued expensesAccounts payable and accrued expenses$37.63 MOther royalty income receivableOther royalty income receivable$23.79 MLiabilitiesLiabilities$7.82 BInterest payableInterest payable$19.22 MAvailable for sale debt securitiesAvailable for sale debt securities$12.10 MAssetsAssets$17.61 BOther current liabilitiesOther current liabilities$18.60 MOther current assetsOther current assets$3.08 MNon-current liabilitiesNon-current liabilities$6.64 BLong-term debtLong-term debt$6.62 BNon-current assetsNon-current assets$15.77 BEquityEquity$9.79 BOther liabilitiesOther liabilities$17.90 MFinancial royalty assets, netFinancial royalty assets, net$15.03 BGross equity (calculated)Gross equity(calculated)$9.79 BAdditional paid-in capitalAdditional paid-in capital$4.21 BRetained earningsRetained earnings$2.48 BEquity method investmentsEquity method investments$336.21 MCommon stock - Class R Redeemable SharesCommon stock - Class R Redeemable Shares$63.00 KAvailable for sale debt securitiesAvailable for sale debt securities$219.00 MCommon stock - Class A Ordinary SharesCommon stock - Class A Ordinary Shares$43.00 KEquity securitiesEquity securities$141.08 MNon-controlling interestsNon-controlling interests$3.10 BOther assetsOther assets$36.71 MTreasury interestsTreasury interests−$2.65 M
Chart details

Royalty Pharma plc (RPRX) FY2025 Q1 Balance Sheet

Balance sheet as of 2025-03-31. The chart shows assets, liabilities and equity at that date.

Assets
17,608,256,000 US dollars
Current assets
1,843,243,000 US dollars
Non-current assets
15,765,013,000 US dollars
Liabilities
7,819,599,000 US dollars
Current liabilities
1,182,852,000 US dollars
Non-current liabilities
6,636,747,000 US dollars
Equity
9,788,657,000 US dollars
Noncontrolling interest
3,100,010,000 US dollars. Included in consolidated equity; this amount is not added again.
Cash and cash equivalents
1,087,720,000 US dollars
Financial royalty assets
716,559,000 US dollars
Other royalty income receivable
23,785,000 US dollars
Available for sale debt securities
12,100,000 US dollars
Other current assets
3,079,000 US dollars
Financial royalty assets, net
15,032,015,000 US dollars
Equity method investments
336,208,000 US dollars
Available for sale debt securities
219,000,000 US dollars
Equity securities
141,083,000 US dollars
Other assets
36,707,000 US dollars
Current portion of long-term debt
998,605,000 US dollars
Distributions payable to non-controlling interests
108,796,000 US dollars
Accounts payable and accrued expenses
37,630,000 US dollars
Interest payable
19,221,000 US dollars
Other current liabilities
18,600,000 US dollars
Long-term debt
6,618,847,000 US dollars
Other liabilities
17,900,000 US dollars
Additional paid-in capital
4,210,531,000 US dollars
Retained earnings
2,480,664,000 US dollars
Common stock - Class R Redeemable Shares
63,000 US dollars
Common stock - Class A Ordinary Shares
43,000 US dollars
Deferred shares, $0.000001 par value; issued and outstanding: 2025–394,513 and 2024–392,255
0 US dollars
Common stock - Class B Ordinary Shares
0 US dollars
Non-controlling interests
3,100,010,000 US dollars
Treasury interests
negative 2,654,000 US dollars
Gross equity (calculated)
9,791,311,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
Royalty Pharma plc (RPRX) FY2025 Q1 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!